Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …

Tumor biopsy is the standard method for cancer diagnosis and provides an important
sample for pathological assessment. With the development of precision medicine, liquid …

Circulating cell free tumour DNA (ctDNA) maintains the same genomic alterations that are
present in the corresponding tumour, thereby allowing for quantitative and qualitative real …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that
has come from primary or metastatic cancer sites. Neoplasm-specific genetic and epigenetic …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Liquid biopsy is a minimally invasive approach to obtain circulating materials that originate
from tumor cells through the sampling of body fluids, mainly peripheral blood. Because of its …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Colorectal cancer (CRC) is currently the most common type of cancer in Japan, and its
prognosis has improved because of development of diagnosis and advancement in …

Background Cancer cells release circulating tumor DNA (ctDNA) into the bloodstream,
which can now be quantified and examined using novel high-throughput sequencing …